• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- New group aims to boost global AMR surveillance

Shiloh

Editor, Senior Moderator
Source: http://www.cidrap.umn.edu/news-perspective/2018/01/new-group-aims-boost-global-amr-surveillance


New group aims to boost global AMR surveillance
Filed Under:
Antimicrobial Stewardship
Chris Dall | News Reporter | CIDRAP News
| Jan 30, 2018

UK-based charitable organization the Wellcome Trust has announced the launch of a new effort to help countries track, share, and analyze information about antimicrobial resistance (AMR).
SEDRIC (Surveillance and Epidemiology of Drug-Resistant Infections Consortium) will bring together international experts in infectious diseases, epidemiology, and human and animal health to identify gaps in AMR surveillance, help countries strengthen and sustain their capacity to collect data on drug-resistant pathogens, and improve global coordination. The group will provide technical expertise and knowledge to help improve surveillance networks and look at how technology can be used to better understand resistance mechanisms and how infections spread.
"Drug-resistant infections are, like us, international travelers," Sharon Peacock, PhD, MRCP, chair of the group and an expert-in-residence at Wellcome Trust, said in a statement today. "We need to track which borders they cross, and how quickly. Without detailed and up-to-date information we cannot effectively intervene."
Peacock added that people on all levels, from healthcare providers to public health officials to policymakers, need to better understand where patients are acquiring bacteria that cause infections. "Are they acquiring bacteria from other patients, from healthcare settings, water or food, or the general environment?" she asked.
Examples of technology that Peacock said could help answer these questions are genomic testing and bacterial sequencing, which can help researchers identify the mechanisms of resistance and how it spreads.
[h=3]Building on other surveillance efforts[/h] Peacock said SEDRIC will build on the work of the World Health Organization's (WHO's) Global Antimicrobial Resistance Surveillance System (GLASS), which yesterday released its first report, containing AMR data from 22 countries. GLASS was launched in 2015 to standardize the collection and sharing of AMR surveillance data across the globe, and is helping countries in their efforts to establish surveillance networks that can track the rise and spread of drug-resistant infections.
The WHO hailed the GLASS report as an important first step in efforts to establish a coordinated system of global AMR surveillance, but also noted that the data varied widely because of differences in surveillance capabilities. The report said that low- and middle-income nations face several challenges in building surveillance systems, including lack of funds and poor healthcare infrastructure.
SEDRIC is the latest effort by Wellcome Trust to improve knowledge on the global impact and scale of AMR. In October, Wellcome announced an investment of ?2.4 million ($3.2 million US) in the Global Burden of Disease AMR project, which will be collecting data from all over the world to create a map of disease and deaths caused by drug-resistant infections.
See also:
Jan 30 Wellcome Trust statement on SEDRIC
Jan 29 CIDRAP News story "WHO releases its first report on global antibiotic resistance"
 
Back
Top Bottom